Article ; Online: The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy.
2022 Volume 21, Issue 4, Page(s) 790–807
Abstract: ... AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches ...
Abstract | After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID-19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons. |
---|---|
MeSH term(s) | Bayes Theorem ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans |
Chemical Substances | COVID-19 Vaccines |
Language | English |
Publishing date | 2022-07-12 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 2083706-9 |
ISSN | 1539-1612 ; 1539-1604 |
ISSN (online) | 1539-1612 |
ISSN | 1539-1604 |
DOI | 10.1002/pst.2226 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.